CADL
Candel Therapeutics, Inc.
$9.64
-0.23 (-2.33%)
At close · Jul 15
Market Cap
$694.60M
Shares
73,270,239
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.64
Open$9.91
Day$9.59–9.98
52W$4.35–11.36
Avg vol 30d2.0M
Short int16.1M · 22.0% float · 6.0d
Short vol54%
Last earningsMay 20, 2026
DataJul 2021–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Feb 23, 2028
Est · unconfirmed
· in 84 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+10%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
75%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
+53%
trailing
YTD return
+71%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
3 of 114 funds reported for Jun 30 · net +79.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.02% of float · ▲ +18.5% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+59%
Y/Y
Free cash flow
$-38.9M
Balance sheet
$119.2M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
75%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
3 of 114 funds reported for Jun 30 · net +79.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.02% of float · ▲ +18.5% MoM · 6.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
114 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $10 · 75%
52-wk high $11
vs 200-day avg +53%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CADL
this stock
Candel Therapeutics, Inc.
|
$694.60M | +70.6% | +0.0% | — | 22.0% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +2.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CADL | -2.4% | +9.9% | +53.0% | -6.4% | +70.6% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -3.7% | +10.0% | +42.9% | -7.5% | +59.9% |